Chairman’s Overview/The Place of Reboxetine in Antidepressant Therapy

LOGIN

REGISTER

SUBSCRIBE


Forgot your login? GET HELP

Because this piece does not have an abstract, we have provided for your benefit the first 3 sentences of the full text.

A wide range of antidepressants is now available including the tricyclic antidepressants (TCAs), monoamine oxidase inhibitors (MAOIs), reversible monoamine oxidase-A inhibitors (RIMAs), serotonin selective reuptake inhibitors (SSRIs), serotonin and norepinephrine reuptake inhibitors (SNRIs), and atypical antidepressants such as mirtazapine and nefazodone. However, clinicians still face a number of problems when selecting the most appropriate antidepressant for a given patient. TCAs are effective in a wide range of patients, but they do have significant drawbacks in terms of their tolerability and safety in overdose, reflecting actions at sites other than those involved in the antidepressant effect.

J Clin Psychiatry 1998;59(suppl 14):26–29